Evanthia Roussos Torres, MD, PhD, discusses the efficacy of entinostat in patients with breast cancer.
Evanthia Roussos Torres, MD, PhD, an assistant professor of medicine at the Keck School of Medicine at the University of Southern California, discusses the efficacy of entinostat in patients with breast cancer.
According to Torres, entinostat monotherapy has mostly been studied in liquid tumors such as leukemias and myelomas. In breast cancer, it has mostly been studied in combination with endocrine therapies and anti-estrogen therapies in order to improve responses to endocrine therapies in patients who were no longer responsive.
The theory is that entinostat would resensitize the tumor microenvironment to estrogen blockade in patients with estrogen receptor and progesterone receptor positive breast cancer. According to Torres, other epigenetic modulating drugs as well as DNMT inhibitors may also sensitive the tumor microenvironment.
0:08 | The efficacy of entinostat (SNDX-275) monotherapy has been primarily studied in the liquid tumors like leukemias and myeloma. Again, I'm not an expert on entinostat specifically, I don't know for sure what the extent of all of those studies is, but as monotherapy and specifically in breast cancer, it was actually being studied in combination with endocrine therapies, anti-estrogen therapies to try and improve the response to endocrine therapies for patients who were no longer responsive. So, the idea was that entinostat would actually resensitize the tumor microenvironment to estrogen blockade for patients with estrogen receptor and progesterone receptor positive breast cancer. And then multiple other epigenetic modulating drugs as well as the DNMT inhibitors, which are DNA methyl transferase inhibitors have been studied in combination with checkpoint inhibition, not just in breast cancer, but in numerous different types of cancer as part of a way to sensitize the tumor microenvironment checkpoint.
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More